Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Sep 04, 2015 8:17pm

148 Views

Post# 24080752

RE:RE:RE:Almylam article.. Wish we could pick up the pace

Jk, I don't see competition between RVX 208 and LDL lowering therapies, only complimentation. There are many risk factors that contribute to MACE. The statins/ezetimibe/PCSK9 inhibitors/ETC1002 take care of LDL. RVX 208 takes care of the HDL and many other beneficial pathways that we've heard about. More importantly, RVX 208 is being used in conjunction with statins, so the MACE reducing effects of RVX 208 are on top of the statin induced LDL lowering. Theoretically, one could sub in PCSK9 inhibitors or ETC1002 for the statin component of the statin /RVX 208 combo and still get the RVX208 MACE effect. BDAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale